S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
NYSE:NBY

NovaBay Pharmaceuticals (NBY) Stock Forecast, Price & News

$0.48
+0.01 (+2.14%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.44
$0.49
50-Day Range
N/A
52-Week Range
$0.42
$4.38
Volume
164,088 shs
Average Volume
3.38 million shs
Market Capitalization
$2.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Price History

NBY Stock News Headlines

See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
29
Year Founded
N/A

Profitability

Net Income
$-10,610,000.00
Pretax Margin
-79.70%

Debt

Sales & Book Value

Annual Sales
$14.40 million
Book Value
$4.04 per share

Miscellaneous

Free Float
4,160,000
Market Cap
$2.01 million
Optionable
Not Optionable
Beta
2.82
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Justin M. Hall Esq. (Age 45)
    Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
    Comp: $364.95k
  • Dr. Audrey Kunin M.D. (Age 64)
    Chief Product Officer
    Comp: $204.4k
  • Mr. Tommy Law (Age 37)
    Controller, Interim CFO & Treasurer
  • Dr. Jeffrey Kunin M.D. (Age 60)
    Pres of DERMAdoctor













NBY Stock - Frequently Asked Questions

How have NBY shares performed in 2023?

NovaBay Pharmaceuticals' stock was trading at $0.5450 at the beginning of the year. Since then, NBY stock has decreased by 12.3% and is now trading at $0.4780.
View the best growth stocks for 2023 here
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($1.27) earnings per share for the quarter. The business earned $4.61 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include OpGen (OPGN) and Abbott Laboratories (ABT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.48.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals (NYSE:NBY) has a market capitalization of $2.01 million and generates $14.40 million in revenue each year. The company earns $-10,610,000.00 in net income (profit) each year or ($9.9465) on an earnings per share basis.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell Street, Suite 1150, eleventh floor, EmeryVille, CA 94608, United States. The official website for the company is novabay.com. The company can be reached via phone at 510-899-8800, via email at jcain@lhai.com, or via fax at 510-474-1577.

This page (NYSE:NBY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -